These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 32992358)
1. Preoperative Differentiation of Benign and Malignant Non-epithelial Ovarian Tumors: Clinical Features and Tumor Markers. Gomes TA; Campos EA; Yoshida A; Sarian LO; Andrade LALA; Derchain SF Rev Bras Ginecol Obstet; 2020 Sep; 42(9):555-561. PubMed ID: 32992358 [TBL] [Abstract][Full Text] [Related]
2. Ovarian masses in children and adolescents - an analysis of 521 clinical cases. Zhang M; Jiang W; Li G; Xu C J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):e73-7. PubMed ID: 24157281 [TBL] [Abstract][Full Text] [Related]
3. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers]. Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels. Ahmed AA; Abdou AM Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303 [TBL] [Abstract][Full Text] [Related]
5. Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses. Pitta Dda R; Sarian LO; Barreta A; Campos EA; Andrade LL; Fachini AM; Campbell LM; Derchain S BMC Cancer; 2013 Sep; 13():423. PubMed ID: 24044637 [TBL] [Abstract][Full Text] [Related]
6. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis. Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638 [TBL] [Abstract][Full Text] [Related]
7. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer. Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149 [TBL] [Abstract][Full Text] [Related]
8. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients. Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095 [TBL] [Abstract][Full Text] [Related]
9. Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial. Hasenburg A; Eichkorn D; Vosshagen F; Obermayr E; Geroldinger A; Zeillinger R; Bossart M BMC Cancer; 2021 Sep; 21(1):1037. PubMed ID: 34530759 [TBL] [Abstract][Full Text] [Related]
10. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125. Li W; Wang D Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526 [TBL] [Abstract][Full Text] [Related]
11. A retrospective study of reproductive outcomes after fertility-sparing surgery and postoperative adjuvant chemotherapy in malignant ovarian germ cell tumors and sex cord-stromal tumors. Zhang N; Chen R; Hua K; Zhang Y J Ovarian Res; 2017 Jul; 10(1):52. PubMed ID: 28750644 [TBL] [Abstract][Full Text] [Related]
12. Different features of the histopathological subtypes of ovarian tumors in pre- and postmenopausal women. Jung EJ; Eom HM; Byun JM; Kim YN; Lee KB; Sung MS; Kim KT; Jeong DH Menopause; 2017 Sep; 24(9):1028-1032. PubMed ID: 28832426 [TBL] [Abstract][Full Text] [Related]
13. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages. Wang Z; Tao X; Ying C Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130 [TBL] [Abstract][Full Text] [Related]
14. Laparoscopic management of early-stage malignant nonepithelial ovarian tumors: surgical and survival outcomes. Shim SH; Kim DY; Lee SW; Park JY; Kim JH; Kim YM; Kim YT; Nam JH Int J Gynecol Cancer; 2013 Feb; 23(2):249-55. PubMed ID: 23318909 [TBL] [Abstract][Full Text] [Related]
15. [Diagnostic value of CA125, HE4 and Copenhagen Index in differentiating benign from malignant epithelial ovarian tumors]. Gong SP; Chen YN; Zhang YD; Yao W; Chen L; Liu SS; Wu H Nan Fang Yi Ke Da Xue Xue Bao; 2017 May; 37(5):628-632. PubMed ID: 28539285 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. Fujiwara H; Suzuki M; Takeshima N; Takizawa K; Kimura E; Nakanishi T; Yamada K; Takano H; Sasaki H; Koyama K; Ochiai K Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813 [TBL] [Abstract][Full Text] [Related]
17. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084 [TBL] [Abstract][Full Text] [Related]
18. Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors. Landolfo C; Achten ETL; Ceusters J; Baert T; Froyman W; Heremans R; Vanderstichele A; Thirion G; Van Hoylandt A; Claes S; Oosterlynck J; Van Rompuy AS; Schols D; Billen J; Van Calster B; Bourne T; Van Gorp T; Vergote I; Timmerman D; Coosemans A Gynecol Oncol; 2020 Dec; 159(3):811-819. PubMed ID: 32994054 [TBL] [Abstract][Full Text] [Related]
19. Serum Human Epididymis Protein-4 (HE4) - A novel Approach to Differentiate Malignant Frombenign Breast Tumors. Sai Baba KSS; Rehman MA; Pradeep Kumar J; Fatima M; Raju GSN; Uppin SG; Mohammed N Asian Pac J Cancer Prev; 2021 Aug; 22(8):2509-2507. PubMed ID: 34452565 [TBL] [Abstract][Full Text] [Related]
20. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Bandiera E; Romani C; Specchia C; Zanotti L; Galli C; Ruggeri G; Tognon G; Bignotti E; Tassi RA; Odicino F; Caimi L; Sartori E; Santin AD; Pecorelli S; Ravaggi A Cancer Epidemiol Biomarkers Prev; 2011 Dec; 20(12):2496-506. PubMed ID: 22028406 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]